GERMANY INSULIN DRUGS AND DELIVERY DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

GERMANY INSULIN DRUGS AND DELIVERY DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Germany Insulin Drugs and Delivery Devices Market is expected to register a CAGR of more than 0.4% over the forecast period.

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That’s why managing or delaying cases of type 2 diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as continuous glucose monitoring and insulin infusion pumps, are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the insulin market's growth.

Key Market TrendsRising diabetes prevalence

In Germany, Diabetes Population is expected to increase with a CAGR greater than 0.48% over the forecast period.

According to the German Diabetes Centre (DDZ), at least 7.2% of the population in Germany currently lives with diabetes which will increase significantly over the next two decades. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of market growth.

German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin drugs. German diabetes patients have some of the lowest out-of-pocket costs in the world, according to T1 International, an advocacy group for people with diabetes. Stringent government policies and favorable regulations by WHO in Germany are encouraging companies to develop innovative products. Penetration of these products in the German market supports local clinical research organizations (CROs) in their clinical research trials and ensures ease of management, which facilitates the discovery process.

Leading manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.

Therefore, owing to the increasing diabetes prevalence the studied market is anticipated to witness growth over the analysis period.

The Insulin Pumps Segment is Expected to Witness Highest Growth Rate Over the Forecast Period

An insulin pump is a device, which delivers insulin continuously or whenever required automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.

Insulin Pump held a major market share in the insulin delivery devices market in 2021 and is expected to grow with a CAGR of more than 2.7% in the market during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes (T1DM) people. Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating.​ The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.

The use of continuous subcutaneous insulin infusion (CSII or insulin pumps) and continuous glucose monitoring systems (CGMs) has improved the care and quality of life for patients and is widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting. The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly, which is likely to drive segment growth during the forecast period.

Competitive Landscape

The Germany Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.